Mavoglurant
Mavoglurant (AFQ-056) je eksperimentalni kandidat leka za tretman fragilnog X sindroma.[4] On deluje kao antagonist metabotropnog glutamatnog receptora 5 (mGlu5).[5]
Mavoglurant | |||
---|---|---|---|
IUPAC ime |
| ||
Drugi nazivi | AFQ056 | ||
Identifikacija | |||
CAS registarski broj | 543906-09-8 | ||
PubChem[1][2] | 9926832 | ||
ChemSpider[3] | 8102466 | ||
UNII | GT0I9SV4F6 | ||
Jmol-3D slike | Slika 1 | ||
| |||
| |||
Svojstva | |||
Molekulska formula | C19H23NO3 | ||
Molarna masa | 313.39 g mol−1 | ||
| |||
Infobox references |
Mavoglurant razvija Novartis i trenutno je u fazi III kliničkih ispitivanja.[4][6] U slučaju uspešnog ishoda ispitivanja, on će biti privi lek koji tretira poremećaju umesto simptoma fragilnog X sindroma.[7]
Reference
uredi- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ 4,0 4,1 P. Cole (2012). „Mavoglurant”. Drugs of the Future 37 (1): 7–12. DOI:10.1358/dof.2012.37.1.1772147.
- ↑ Levenga, J; Hayashi, S; De Vrij, FM; Koekkoek, SK; Van Der Linde, HC; Nieuwenhuizen, I; Song, C; Buijsen, RA et al. (2011). „AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome”. Neurobiology of disease 42 (3): 311–7. DOI:10.1016/j.nbd.2011.01.022. PMID 21316452.
- ↑ Jacquemont, S.; Curie, A.; Des Portes, V.; Torrioli, M. G.; Berry-Kravis, E.; Hagerman, R. J.; Ramos, F. J.; Cornish, K. et al. (2011). „Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome is Associated with Differential Response to the mGluR5 Antagonist AFQ056”. Science Translational Medicine 3 (64): 64ra1. DOI:10.1126/scitranslmed.3001708. PMID 21209411.
- ↑ „AFQ056 drug improves symptoms in Fragile X patients: Study”. news-medical.net. 9. 1. 2011..